Updated 5/23/19. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.
| Manufacturer Sort descending | Labeler Codes Reviewed | State | OPA Findings | Sanction | Corrective Action Status |
|---|---|---|---|---|---|
Belcher Pharmaceuticals, LLCContact InformationGeneral Counsel |
62250 | FL |
Belcher did not offer covered outpatient drugs to eligible covered entities at the statutory ceiling price. |
Repayment to covered entities |
CAP implemented Audit closure date: May 8, 2019 |
| Cumberland Pharmaceuticals, Inc. | 66220 | TN |
No adverse findings |
None |
N/A |
| Horizon Pharma USA, Inc. |
75987 42238 49663 76325 |
IL |
No adverse findings |
None |
N/A |
| Johnson & Johnson Health Care Systems |
00045 00062 50458 08004 62341 10147 16837 17314 56091 57894 59676 65847 68669 |
NJ |
No adverse findings |
None |
N/A |
| Takeda Pharmaceuticals America, Inc. | 64764 | IL |
No adverse findings |
None |
N/A |